DS3790 enters clinical development as first DXd ADC in hematology from industry-leading ADC portfolio of Daiichi Sankyo

CAR-T Digest - August 2020

Weekly Digest - February 2026

04 February 2026: DS3790 enters clinical development as first DXd ADC in hematology from industry-leading ADC portfolio of Daiichi Sankyo

Daiichi Sankyo has reached a key milestone in hematologic oncology, with the first patient dosed in a first-in-human phase 1/2 clinical trial evaluating DS3790 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma, marking the company’s formal entry of a DXd ADC into hematology
The initiation of this study expands Daiichi Sankyo’s industry-leading DXd ADC portfolio, making DS3790 the company’s seventh DXd-based ADC in clinical development and reinforcing its strategy of leveraging in-house ADC technology to address difficult-to-treat cancers beyond solid tumors
DS3790 is a potential first-in-class CD37-directed antibody drug conjugate, targeting a transmembrane protein highly expressed on malignant B-cells and involved in cell survival, an area of unmet need given that no CD37-targeted therapies are currently approved for any cancer
The global, multicenter phase 1/2 trial will first evaluate DS3790 as a monotherapy, beginning with dose escalation to determine the recommended expansion dose, followed by multiple dose-expansion cohorts; subsequent trial phases will explore DS3790 in combination with other targeted therapies after initial safety and efficacy signals are established
With plans to enroll approximately 420 patients across Asia, Europe, and North America, the study will assess a comprehensive set of endpoints including safety, efficacy, pharmacokinetics, and biomarkers, positioning DS3790 as a potentially important new therapeutic option for patients with B-cell non-Hodgkin lymphoma who continue to face limited durability and poor long-term outcomes after relapse